Omnicell [OMCL] vs 10x Genomics [TXG] Detailed Stock Comparison
Omnicell
NASDAQ
Loading...
10x Genomics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Omnicell wins in 13 metrics, 10x Genomics wins in 5 metrics, with 0 ties. Omnicell appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Omnicell | 10x Genomics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 61.66 | -8.09 | 10x Genomics |
| Price-to-Book Ratio | 1.13 | 1.97 | Omnicell |
| Debt-to-Equity Ratio | 30.42 | 11.22 | 10x Genomics |
| PEG Ratio | 17.13 | -10.07 | 10x Genomics |
| EV/EBITDA | 18.92 | -10.13 | 10x Genomics |
| Profit Margin (TTM) | 2.01% | -13.13% | Omnicell |
| Operating Margin (TTM) | 2.80% | -6.12% | Omnicell |
| EBITDA Margin (TTM) | 2.80% | N/A | N/A |
| Return on Equity | 1.87% | -11.30% | Omnicell |
| Return on Assets (TTM) | 0.49% | -9.71% | Omnicell |
| Free Cash Flow (TTM) | $134.93M | $-6.73M | Omnicell |
| 1-Year Return | -24.53% | -39.84% | Omnicell |
| Price-to-Sales Ratio (TTM) | 1.24 | 2.35 | Omnicell |
| Enterprise Value | $1.40B | $1.16B | Omnicell |
| EV/Revenue Ratio | 1.22 | 1.80 | Omnicell |
| Gross Profit Margin (TTM) | 43.94% | 68.08% | 10x Genomics |
| Revenue per Share (TTM) | $25 | $5 | Omnicell |
| Earnings per Share (Diluted) | $0.50 | $-0.70 | Omnicell |
| Beta (Stock Volatility) | 0.78 | 2.03 | Omnicell |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Omnicell vs 10x Genomics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Omnicell | -0.64% | 3.60% | 3.94% | 21.43% | -27.29% | -30.44% |
| 10x Genomics | -3.98% | -6.04% | 0.33% | 42.41% | 1.91% | -13.39% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Omnicell | -24.53% | -71.93% | -56.14% | -15.02% | 165.78% | 269.66% |
| 10x Genomics | -39.84% | -74.52% | -88.03% | -76.49% | -76.49% | -76.49% |
Performance & Financial Health Analysis: Omnicell vs 10x Genomics
| Metric | OMCL | TXG |
|---|---|---|
| Market Information | ||
| Market Cap | $1.43B | $1.51B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 653,530 | 3,254,710 |
| 90 Day Avg. Volume | 520,253 | 3,636,777 |
| Last Close | $30.83 | $12.29 |
| 52 Week Range | $22.66 - $55.75 | $6.78 - $24.76 |
| % from 52W High | -44.70% | -50.36% |
| All-Time High | $187.29 (Nov 22, 2021) | $208.99 (Jun 28, 2021) |
| % from All-Time High | -83.54% | -94.12% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.13% |
| Quarterly Earnings Growth | 0.51% | 0.10% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | -0.13% |
| Operating Margin (TTM) | 0.03% | -0.06% |
| Return on Equity (TTM) | 0.02% | -0.11% |
| Debt to Equity (MRQ) | 30.42 | 11.22 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $27.22 | $6.25 |
| Cash per Share (MRQ) | $8.69 | $3.61 |
| Operating Cash Flow (TTM) | $147.75M | $18.24M |
| Levered Free Cash Flow (TTM) | $85.81M | $-182,627,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Omnicell vs 10x Genomics
| Metric | OMCL | TXG |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 61.66 | -8.09 |
| Forward P/E | 17.13 | -10.07 |
| PEG Ratio | 17.13 | -10.07 |
| Price to Sales (TTM) | 1.24 | 2.35 |
| Price to Book (MRQ) | 1.13 | 1.97 |
| Market Capitalization | ||
| Market Capitalization | $1.43B | $1.51B |
| Enterprise Value | $1.40B | $1.16B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.22 | 1.80 |
| Enterprise to EBITDA | 18.92 | -10.13 |
| Risk & Other Metrics | ||
| Beta | 0.78 | 2.03 |
| Book Value per Share (MRQ) | $27.22 | $6.25 |
Financial Statements Comparison: Omnicell vs 10x Genomics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | OMCL | TXG |
|---|---|---|
| Revenue/Sales | $290.56M | $154.88M |
| Cost of Goods Sold | $162.88M | $49.44M |
| Gross Profit | $127.68M | $105.45M |
| Research & Development | $21.57M | $64.25M |
| Operating Income (EBIT) | $8.12M | $-48.53M |
| EBITDA | $29.77M | $-32.89M |
| Pre-Tax Income | $10.45M | $-33.51M |
| Income Tax | $4.81M | $852,000 |
| Net Income (Profit) | $5.64M | $-34.36M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | OMCL | TXG |
|---|---|---|
| Cash & Equivalents | $386.83M | $377.06M |
| Total Current Assets | $839.67M | $579.73M |
| Total Current Liabilities | $607.53M | $107.90M |
| Long-Term Debt | $199.72M | $70.63M |
| Total Shareholders Equity | $1.26B | $706.90M |
| Retained Earnings | $375.87M | $-1.50B |
| Property, Plant & Equipment | $130.63M | $55.58M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | OMCL | TXG |
|---|---|---|
| Operating Cash Flow | $28.34M | $35.44M |
| Capital Expenditures | $-11.17M | $-1.89M |
| Free Cash Flow | $10.19M | $32.46M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | OMCL | TXG |
|---|---|---|
| Shares Short | 1.91M | 14.26M |
| Short Ratio | 4.36 | 3.41 |
| Short % of Float | 0.06% | 0.19% |
| Average Daily Volume (10 Day) | 653,530 | 3,254,710 |
| Average Daily Volume (90 Day) | 520,253 | 3,636,777 |
| Shares Outstanding | 46.38M | 122.29M |
| Float Shares | 44.85M | 109.56M |
| % Held by Insiders | 0.02% | 0.02% |
| % Held by Institutions | 1.05% | 1.06% |
Dividend Analysis & Yield Comparison: Omnicell vs 10x Genomics
| Metric | OMCL | TXG |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |